Bizily Scott sold $21K of FDMT

4D Molecular Therapeutics (FDMT) reported that its Phase III trials for 4D-150 gene therapy for wet AMD are fully enrolled, with 523 patients in North America and 531 globally. The primary endpoint is non-inferiority in visual acuity compared to aflibercept. The company expects results in 2027 and has a cash runway into 2028.

Ocular Therapeutix (OCUL) shares dropped 22% as competitors Kodiak Sciences (KOD) and 4D Molecular Therapeutics (FDMT) reported positive updates on their wet AMD treatments. KOD's DAYBREAK study met goals, while FDMT's 4D-150 showed lasting benefits. OCUL's AXPAXLI is in development, with FDA filing planned for late 2026.

4D Molecular Therapeutics, Inc. (FDMT) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On September 28, 2026, 4D Molecular Therapeutics, Inc. (the “Company”) reported that the first patients have been enrolled across multiple sites in the 4SIGHT Phase 3 clinical trial evaluating 4D-150 for the treatment of diabetic macular edema (“DME”). The

Compass Point upgraded Coinbase (COIN) to Neutral with a $177 price target, up from $130. Other upgrades include 4D Molecular Therapeutics (FDMT), Affirm (AFRM), Chime Financial (CHYM), and Bullish (BLSH) by their respective analysts. COIN closed at $175.26 on Friday.

Ocular Therapeutix (OCUL) and 4D Molecular (FDMT) shares rose after EyePoint Pharmaceuticals (EYPT) reported its DURAVYU trial missed its primary goal. Clear Street maintained a 'Buy' rating on OCUL, while B. Riley set a $37 target for FDMT. EYPT's stock fell 67% on the news, with OCUL and FDMT gaining 6% and 19% respectively.

Ocular Therapeutix (OCUL) and 4D Molecular (FDMT) rose after EyePoint Pharmaceuticals (EYPT) said its DURAVYU late-stage wet AMD trial missed its main goal versus Eylea. Analysts cited potential competitive relief for OCUL’s Axpaxli and trial design benefits for FDMT’s 4D-150. OCUL gained 6%, FDMT 19%; EYPT shares fell 67%.